×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Applied Genetic Technologies Corp. (AGTC) NASDAQ

$0.39 0 (1.23%)

Market Cap: -

As of 11/30/22 04:00 PM EST. Market closed.

(AGTC)

Applied Genetic Technologies Corp. (AGTC)
NASDAQ

$0.39
0 (1.23%)

Market Cap: -

As of 11/30/22 04:00 PM EST. Market closed.

Add to Portfolio

Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's ... read more

Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
Susan Washer
Full Time Employees
83
CEO Compensation (Base)
$487,000
CEO Compensation (Total)
$1.50M
URL
Address
14193 Nw 119Th Terrace, Suite #10, Florida, Alachua, 32615.
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
Susan Washer
Full Time Employees
83
CEO Compensation (Base)
$487,000
CEO Compensation (Total)
$1.50M
Address
14193 Nw 119Th Terrace, Suite #10, Florida, Alachua, 32615.
PRICE CHART FOR APPLIED GENETIC TECHNOLOGIES CORP
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$0.39
Days Range
$0.37 - $0.40
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
67,632,195
Open
-
Previous Close
$0.39
Days Range
$0.37 - $0.40
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
67,632,195
FINANCIAL STATEMENTS FOR APPLIED GENETIC TECHNOLOGIES CORP
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR APPLIED GENETIC TECHNOLOGIES CORP
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Potter Stephen WChief Business OfficerJul 01, 2022 Sale$0.778,0706,25055,883Jul 01, 2022, 04:01 PM
Reynolds Gerald AnthonyChief Accounting OfficerMay 27, 2022 Sale$0.853,9943,37621,006May 31, 2022, 04:24 PM
Washer Susan B.President and CEOFeb 18, 2022 Option Exercise$0.35120,68642,240152,971Feb 22, 2022, 09:34 PM
Washer Susan B.President and CEOFeb 18, 2022 Sale$2.189,95021,691143,021Feb 22, 2022, 09:34 PM
Washer Susan B.President and CEONov 01, 2021 Option Exercise$3.503,87713,57032,285Nov 03, 2021, 07:19 PM
Potter Stephen WChief Business OfficerAug 15, 2021 Option Exercise$3.585,72420,49263,953Aug 17, 2021, 06:42 PM
Potter Stephen WVP and Chief Business OfficerAug 15, 2020 Option Exercise$5.775,72333,02234,677Aug 18, 2020, 06:22 PM
Shearman Mark SChief Scientific OfficerAug 15, 2020 Option Exercise$5.775,72333,02233,277Aug 18, 2020, 06:15 PM
Krol Patrick Johan Hendrik10% OwnerDec 26, 2019 Sale$5.2481,162425,2891,780,762Dec 30, 2019, 04:33 PM
Krol Patrick Johan Hendrik10% OwnerNov 19, 2019 Buy$2.792,5447,0981,861,924Nov 26, 2019, 05:17 PM
Washer Susan B.President and CEOSep 18, 2019 Option Exercise$3.505,70019,95028,408Sep 20, 2019, 04:22 PM
Feinsod MatthewInterim Chief Medical OfficerJul 11, 2019 Option Exercise$3.755922,22056,052Jul 15, 2019, 04:45 PM
Feinsod MatthewInterim Chief Medical OfficerJun 11, 2019 Option Exercise$3.706852,53554,644Jun 20, 2019, 04:39 PM
Feinsod MatthewInterim Chief Medical OfficerJun 11, 2019 Option Exercise$3.776852,58254,644Jun 13, 2019, 07:21 PM
Koenig ScottDirectorMay 28, 2019 Option Exercise$0.3532,01811,20634,246May 30, 2019, 04:04 PM
Feinsod MatthewInterim Chief Medical OfficerMay 13, 2019 Option Exercise$4.066852,78153,329May 20, 2019, 04:02 PM
Feinsod MatthewInterim Chief Medical OfficerMay 13, 2019 Option Exercise$4.206852,87753,329May 15, 2019, 04:21 PM
Feinsod MatthewInterim Chief Medical OfficerApr 11, 2019 Option Exercise$4.616062,79452,014Apr 15, 2019, 05:42 PM
Feinsod MatthewInterim Chief Medical OfficerMar 11, 2019 Option Exercise$3.976672,64850,620Mar 13, 2019, 05:16 PM
Feinsod MatthewInterim Chief Medical OfficerFeb 11, 2019 Option Exercise$3.297912,60249,287Feb 13, 2019, 06:30 PM
Feinsod MatthewInterim Chief Medical OfficerJan 11, 2019 Option Exercise$3.207132,28248,078Jan 15, 2019, 07:58 PM
Rosen JamesDirectorDec 14, 2018 Buy$3.381,0003,3811,000Dec 18, 2018, 08:29 PM
Aliski WilliamDirectorDec 14, 2018 Buy$3.256,00019,4778,500Dec 18, 2018, 08:20 PM
Sullivan William A.Chief Financial OfficerDec 14, 2018 Buy$3.333,0009,9903,000Dec 18, 2018, 08:10 PM
Shearman Mark SChief Scientific OfficerDec 14, 2018 Sale$3.353,00010,0530Dec 18, 2018, 07:58 PM
Washer Susan B.President and CEODec 14, 2018 Buy$3.342,3807,94922,708Dec 18, 2018, 07:36 PM
Feinsod MatthewInterim Chief Medical OfficerDec 11, 2018 Option Exercise$6.116113,73346,791Dec 13, 2018, 09:23 PM
Feinsod MatthewInterim Chief Medical OfficerNov 12, 2018 Option Exercise$7.056854,82945,402Nov 14, 2018, 04:43 PM
Feinsod MatthewInterim Chief Medical OfficerOct 11, 2018 Option Exercise$6.466123,95444,087Oct 15, 2018, 07:01 PM
Feinsod MatthewInterim Chief Medical OfficerSep 11, 2018 Option Exercise$3.926852,68942,699Sep 13, 2018, 05:04 PM
Feinsod MatthewInterim Chief Medical OfficerAug 13, 2018 Option Exercise$4.005922,36841,384Aug 15, 2018, 07:07 PM
Feinsod MatthewInterim Chief Medical OfficerJul 11, 2018 Option Exercise$4.156852,84339,976Jul 13, 2018, 05:57 PM
Feinsod MatthewInterim Chief Medical OfficerJun 11, 2018 Option Exercise$4.556062,75738,661Jun 13, 2018, 07:33 PM
Feinsod MatthewInterim Chief Medical OfficerMay 16, 2018 Option Exercise$5.603,42519,18037,267May 18, 2018, 06:17 PM
Feinsod MatthewInterim Chief Medical OfficerMay 11, 2018 Option Exercise$4.906853,35740,692May 15, 2018, 04:34 PM
Feinsod MatthewInterim Chief Medical OfficerApr 11, 2018 Option Exercise$4.006852,74039,377Apr 13, 2018, 04:20 PM
Feinsod MatthewInterim Chief Medical OfficerFeb 09, 2018 Option Exercise$3.957332,89526,729Apr 06, 2018, 08:45 PM
Feinsod MatthewInterim Chief Medical OfficerJan 11, 2018 Option Exercise$4.307913,40125,462Apr 06, 2018, 08:26 PM
Feinsod MatthewInterim Chief Medical OfficerDec 11, 2017 Option Exercise$3.753,39512,73124,253Apr 06, 2018, 08:15 PM
Feinsod MatthewInterim Chief Medical OfficerMar 12, 2018 Option Exercise$4.306672,86832,126Mar 14, 2018, 07:49 PM
Feinsod MatthewInterim Chief Medical OfficerJan 11, 2018 Option Exercise$4.308553,67728,793Jan 16, 2018, 08:29 PM
Magovcevic IvanaDirectorNov 16, 2016 Buy$9.633,00028,8753,000Nov 17, 2016, 04:53 PM
Chulay Jeffrey D.VP and Chief Medical OfficerNov 01, 2016 Sale$7.051,0007,05120,400Nov 02, 2016, 06:42 PM
Chulay Jeffrey D.VP and Chief Medical OfficerOct 19, 2016 Option Exercise$0.3510,0003,50021,400Oct 27, 2016, 08:24 PM
Chulay Jeffrey D.VP and Chief Medical OfficerOct 19, 2016 Option Exercise$0.351,00035012,400Oct 21, 2016, 06:03 PM
Potter Stephen WSee RemarksSep 20, 2016 Buy$8.694003,4761,400Sep 27, 2016, 05:12 PM
Potter Stephen WSee RemarksSep 16, 2016 Buy$8.971,0008,9701,000Sep 27, 2016, 05:12 PM
Shearman Mark SChief Scientific OfficerSep 22, 2016 Buy$8.873,00026,6013,000Sep 26, 2016, 05:20 PM
BULLOCK LAWRENCE EChief Financial OfficerSep 19, 2016 Buy$8.7510,00087,50010,000Sep 20, 2016, 04:51 PM
Washer Susan B.See RemarksAug 29, 2016 Option Exercise$3.505,32818,64820,328Aug 30, 2016, 05:43 PM
Chulay Jeffrey D.VP and Chief Medical OfficerMay 25, 2016 Option Exercise$3.502,0007,00011,900May 26, 2016, 07:03 PM
Chulay Jeffrey D.VP and Chief Medical OfficerMay 11, 2016 Option Exercise$3.504,00014,0009,900May 26, 2016, 07:00 PM
GLAXOSMITHKLINE PLCFormer 10% OwnerFeb 23, 2015 Sale$22.00503,15011,069,6021,436,448Feb 24, 2015, 04:05 PM
GLAXOSMITHKLINE PLC10% OwnerDec 10, 2014 Sale$21.1810,000211,7601,979,598Feb 12, 2015, 06:31 PM
GLAXOSMITHKLINE PLC10% OwnerDec 18, 2014 Sale$21.0112,000252,1361,939,598Feb 12, 2015, 06:31 PM
GLAXOSMITHKLINE PLC10% OwnerDec 17, 2014 Sale$21.008,000168,0001,951,598Feb 12, 2015, 06:31 PM
GLAXOSMITHKLINE PLC10% OwnerDec 12, 2014 Sale$21.247,500159,2941,959,598Feb 12, 2015, 06:31 PM
GLAXOSMITHKLINE PLC10% OwnerDec 11, 2014 Sale$21.2812,500266,0351,967,098Feb 12, 2015, 06:31 PM
Menichella Daniel LV.P. & Chief Business OfficerJan 23, 2015 Option Exercise$4.901,9969,7801,996Jan 26, 2015, 06:04 PM
Menichella Daniel LV.P. & Chief Business OfficerJan 23, 2015 Sale$24.901,99649,7000Jan 26, 2015, 06:04 PM
Menichella Daniel LV.P. & Chief Business OfficerDec 22, 2014 Option Exercise$4.909,00044,1009,000Dec 23, 2014, 02:54 PM
Menichella Daniel LV.P. & Chief Business OfficerDec 22, 2014 Sale$20.839,000187,4700Dec 23, 2014, 02:54 PM
GLAXOSMITHKLINE PLC10% OwnerApr 01, 2014 Buy$12.00103,7621,245,1441,989,598Apr 02, 2014, 12:42 PM
Wu SamuelDirectorApr 01, 2014 Buy$12.0075,735908,8201,452,196Apr 01, 2014, 04:31 PM
Rosen JamesDirectorApr 01, 2014 Buy$12.0062,871754,4521,205,537Apr 01, 2014, 04:31 PM
ORONSKY ARNOLD LDirectorApr 01, 2014 Buy$12.0075,736908,8321,452,216Apr 01, 2014, 04:30 PM
MedImmune Ventures, Inc.10% OwnerApr 01, 2014 Buy$12.0075,735908,8201,452,196Apr 01, 2014, 04:29 PM
Carroll JillDirectorApr 01, 2014 Buy$12.00103,7621,245,1441,989,598Apr 01, 2014, 04:29 PM
Alta Partners VIII, L.P.10% OwnerApr 01, 2014 Buy$12.00155,6451,867,7402,984,400Apr 01, 2014, 04:28 PM
INTERWEST PARTNERS VIII LP10% OwnerApr 01, 2014 Buy$12.0075,376904,5121,452,216Apr 01, 2014, 02:06 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Potter Stephen WChief Business Officer07/01/20226,250
Reynolds Gerald AnthonyChief Accounting Officer05/27/20223,376
Washer Susan B.President and CEO02/18/202242,240
Washer Susan B.President and CEO02/18/202221,691
Washer Susan B.President and CEO11/01/202113,570
Potter Stephen WChief Business Officer08/15/202120,492
Potter Stephen WVP and Chief Business Officer08/15/202033,022
Shearman Mark SChief Scientific Officer08/15/202033,022
Krol Patrick Johan Hendrik10% Owner12/26/2019425,289
Krol Patrick Johan Hendrik10% Owner11/19/20197,098
Washer Susan B.President and CEO09/18/201919,950
Feinsod MatthewInterim Chief Medical Officer07/11/20192,220
Feinsod MatthewInterim Chief Medical Officer06/11/20192,535
Feinsod MatthewInterim Chief Medical Officer06/11/20192,582
Koenig ScottDirector05/28/201911,206
Feinsod MatthewInterim Chief Medical Officer05/13/20192,781
Feinsod MatthewInterim Chief Medical Officer05/13/20192,877
Feinsod MatthewInterim Chief Medical Officer04/11/20192,794
Feinsod MatthewInterim Chief Medical Officer03/11/20192,648
Feinsod MatthewInterim Chief Medical Officer02/11/20192,602
Feinsod MatthewInterim Chief Medical Officer01/11/20192,282
Rosen JamesDirector12/14/20183,381
Aliski WilliamDirector12/14/201819,477
Sullivan William A.Chief Financial Officer12/14/20189,990
Shearman Mark SChief Scientific Officer12/14/201810,053
Washer Susan B.President and CEO12/14/20187,949
Feinsod MatthewInterim Chief Medical Officer12/11/20183,733
Feinsod MatthewInterim Chief Medical Officer11/12/20184,829
Feinsod MatthewInterim Chief Medical Officer10/11/20183,954
Feinsod MatthewInterim Chief Medical Officer09/11/20182,689
Feinsod MatthewInterim Chief Medical Officer08/13/20182,368
Feinsod MatthewInterim Chief Medical Officer07/11/20182,843
Feinsod MatthewInterim Chief Medical Officer06/11/20182,757
Feinsod MatthewInterim Chief Medical Officer05/16/201819,180
Feinsod MatthewInterim Chief Medical Officer05/11/20183,357
Feinsod MatthewInterim Chief Medical Officer04/11/20182,740
Feinsod MatthewInterim Chief Medical Officer02/09/20182,895
Feinsod MatthewInterim Chief Medical Officer01/11/20183,401
Feinsod MatthewInterim Chief Medical Officer12/11/201712,731
Feinsod MatthewInterim Chief Medical Officer03/12/20182,868
Feinsod MatthewInterim Chief Medical Officer01/11/20183,677
Magovcevic IvanaDirector11/16/201628,875
Chulay Jeffrey D.VP and Chief Medical Officer11/01/20167,051
Chulay Jeffrey D.VP and Chief Medical Officer10/19/20163,500
Chulay Jeffrey D.VP and Chief Medical Officer10/19/2016350
Potter Stephen WSee Remarks09/20/20163,476
Potter Stephen WSee Remarks09/16/20168,970
Shearman Mark SChief Scientific Officer09/22/201626,601
BULLOCK LAWRENCE EChief Financial Officer09/19/201687,500
Washer Susan B.See Remarks08/29/201618,648
Chulay Jeffrey D.VP and Chief Medical Officer05/25/20167,000
Chulay Jeffrey D.VP and Chief Medical Officer05/11/201614,000
GLAXOSMITHKLINE PLCFormer 10% Owner02/23/201511,069,602
GLAXOSMITHKLINE PLC10% Owner12/10/2014211,760
GLAXOSMITHKLINE PLC10% Owner12/18/2014252,136
GLAXOSMITHKLINE PLC10% Owner12/17/2014168,000
GLAXOSMITHKLINE PLC10% Owner12/12/2014159,294
GLAXOSMITHKLINE PLC10% Owner12/11/2014266,035
Menichella Daniel LV.P. & Chief Business Officer01/23/20159,780
Menichella Daniel LV.P. & Chief Business Officer01/23/201549,700
Menichella Daniel LV.P. & Chief Business Officer12/22/201444,100
Menichella Daniel LV.P. & Chief Business Officer12/22/2014187,470
GLAXOSMITHKLINE PLC10% Owner04/01/20141,245,144
Wu SamuelDirector04/01/2014908,820
Rosen JamesDirector04/01/2014754,452
ORONSKY ARNOLD LDirector04/01/2014908,832
MedImmune Ventures, Inc.10% Owner04/01/2014908,820
Carroll JillDirector04/01/20141,245,144
Alta Partners VIII, L.P.10% Owner04/01/20141,867,740
INTERWEST PARTNERS VIII LP10% Owner04/01/2014904,512
Load More Insider Transactions
BUYBACK ANNOUNCEMENT(S) FOR APPLIED GENETIC TECHNOLOGIES CORP
LOADING...